Opinion|Videos|May 9, 2025
Risk Factors of CHE
Author(s)Raj Chovatiya, MD, PhD
An expert discusses how risk factors for chronic hand eczema (CHE) include atopic dermatitis, filaggrin mutations, contact allergies, environmental conditions, and occupational exposures, with hand eczema being the most common occupational skin disease.
Advertisement
Video content above is prompted by the following:
Risk Factors of CHE
Key Themes:
- Environmental risk factors: Occupational exposures, weather conditions, decreased indoor humidity, and tobacco use.
- Physiological risk factors: Atopic dermatitis history, early onset of hand eczema, filaggrin mutations, and contact allergies.
- Occupational considerations: Highest risk industries include hairdressing, health care, food service, cleaning, and manufacturing, with CHE being the most common occupational skin disease.
Notable Insights:
Dr Chovatiya highlighted the difficulty in risk factor modification: "Even though sometimes we can do really good detective work...the actual implementation of changes to practically help people on a day-to-day basis can be very, very difficult."
Advertisement
Related to this article
In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.
Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.
In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026.
CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.
In patients with compensated MASH cirrhosis, Baveno VII and ANTICIPATE-NASH showed moderate agreement with HVPG and underestimated CSPH prevalence.
Robert Mentz, MD, discusses mentorship, trial recruitment, journal growth, and surgical partnerships in heart failure care.
At GOLD 2026, Alvar AgustĂ, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.
In the phase 2b VISTAS trial, volixibat improved sleep vs placebo in PSC with cholestatic pruritus, and itch responders saw greater fatigue and sleep gains.
Advertisement
Advertisement
Trending on HCPLive
1
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
2
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
3
ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC
4
Moving the Needle in Medicine: Mentorship, Teams, and Heart Failure Leadership, With Robert Mentz, MD
5